Eltrombopag(Revolade)Eltromdx

Introduction of Eltrombopag

As a thrombopoietin receptor agonist, this product increases platelet counts and exerts a hemostatic effect, reducing or preventing bleeding and alleviating thrombocytopenia-related symptoms.

Indications

This product is primarily indicated for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP) in patients aged ≥12 years who have an inadequate response to treatments such as corticosteroids, immunoglobulins, or who have relapsed after splenectomy.

This product is only indicated for bleeding caused by thrombocytopenia and is not suitable for bleeding due to other conditions or of unknown etiology.

Overview

Important Precautions Before Use

For adolescents aged 12 years and older, elderly patients, pregnant and breastfeeding women, patients with hepatic or renal impairment, and those at risk of thromboembolism, the benefits and risks should be carefully weighed, and the medication should be used cautiously under medical supervision.

When used in combination with other medications, the dosage or frequency may be adjusted; use strictly as directed by a physician.

Dosage and Administration

Administration Method

Oral administration. Do not chew, crush, or mix with food or liquid. Take on an empty stomach (at least 1 hour before or 2 hours after a meal). If the meal contains antacids, dairy products, or supplements containing iron, calcium, magnesium, aluminum, selenium, or zinc, separate dosing by at least 2 hours before or 4 hours after the meal.

Dosage

Initial dose for adults: 25 mg once daily.

Dose adjustment: Increase by 25 mg increments as needed; maximum daily dose is 75 mg, administered once daily.

Monitoring: Monitor platelet counts weekly during treatment. Evaluate treatment response after 2 weeks and adjust dosage as necessary. Follow physician instructions for dosing details.

Use in Special Populations

Renal impairment: No dosage adjustment is generally required, but use cautiously due to limited clinical experience; monitor renal function closely. Follow physician instructions.

Hepatic impairment: Eltrombopag has hepatotoxic potential; use cautiously. If necessary, administer under medical supervision and monitor liver function closely.

Other populations (children, adolescents, elderly, pregnant/breastfeeding women, thromboembolic risk): Use cautiously under medical supervision; adjust dosage as needed.

Missed Dose Management

If a dose is missed during treatment, continue with the original dosage and administration schedule.

Do not take a double dose to make up for the missed one, as this may cause toxic reactions.

If you are unsure about the dosage, consult a physician or pharmacist.

Post-Administration Precautions

Monitor for adverse reactions during treatment; report to a physician promptly for symptomatic management.

Hepatic injury may occur; monitor liver function regularly. Consult a physician for details.

Avoid falls, injuries, or collisions during treatment.

Discontinue use if the product’s appearance changes. Keep out of reach of children.

Special Population Use

Pregnant women

Animal studies indicate potential fetal risk. Use only if the potential benefit justifies the risk. If pregnant or planning pregnancy, inform your physician immediately to discuss the optimal treatment plan.

Breastfeeding women

Animal studies show the drug may be excreted in breast milk. Use with caution; discontinue breastfeeding if treatment is necessary. Consult a physician for details.

Adolescents and children

No safety or efficacy data for pediatric use. Use in patients <12 years is not recommended.

Elderly patients

May be more sensitive to the drug, with increased risk of hepatic injury. Use cautiously; adjust dosage as directed by a physician if necessary.

Patients with hepatic impairment

Eltrombopag has hepatotoxic potential. Use with caution; initiate at a low dose if necessary. Consult a physician for details.

Patients with renal impairment

Use with caution; monitor renal function closely if treatment is necessary. Consult a physician for details.

Other

Patients at risk of thromboembolism (e.g., advanced age, malignant tumors, prolonged bed rest, hormonal contraception or replacement therapy, surgery or trauma, obesity, smokers) should use with caution.

Side Effects

Most severe adverse reactions

Hepatotoxicity and thrombosis, presenting as jaundice (yellowing of eyes/skin), altered mental status, sudden limb incoordination, or slurred speech.

Common adverse reactions

Headache, decreased appetite, insomnia, nausea, cough, dry eyes, cataracts, diarrhea, alopecia, pruritus, musculoskeletal pain, fever, fatigue, asthenia, chills, peripheral edema, abnormal liver function, menorrhagia, paresthesia.

Uncommon adverse reactions

Pharyngitis, anemia, gout, depression, hypoesthesia, blurred vision, dizziness, tachycardia, dry mouth, hyperhidrosis, renal failure.

Not all side effects will occur, but consult a physician immediately if any develop.

Contraindications

Contraindicated in patients with hypersensitivity to eltrombopag olamine or any excipient in this product.

Discontinue Eltrombopag Olamine Tablets Immediately

Discontinue use if a patient with normal pretreatment liver function develops ≥3× elevation of alanine aminotransferase (ALT) with persistent elevation, or concurrent elevated direct bilirubin or hepatic impairment.

For patients with thromboembolic risk factors, monitor platelet counts closely during treatment. If platelet counts exceed the target level, consider dose reduction or discontinuation. Consult a physician for details.

Note: Discontinuation for the above conditions or other severe adverse reactions must be evaluated by a physician and guided by medical advice; do not stop treatment arbitrarily.

Recommended articles

Contact Information

If any issues arise, please contact us immediately.

Email:haiousales@gmail.com

WhatsApp